Our approach
Traditional drug development remains a critical bottleneck to human health. We are engineering a new standard of discovery: one defined by unprecedented speed, cost-efficiency, and molecular precision.
Neuro-symbolic AI
Frontier models built on first principles. We codify deep scientific domain rules from chemistry, physics, and biology.
End-to-end pipeline
From target to trial, we combine the scale and accuracy of AI with the human expertise.
Multiple modalities
A modality-versatile platform engineered to accelerate discovery across small molecules, antibodies, and siRNA therapies alike.
Global ecosystem
A worldwide partnership infrastructure to redefine clinical efficiency by drastically reducing timelines without compromising patient safety.
Humans in the loop
By layering human clinical judgment over high-velocity AI outputs, we ensure that our platform delivers only the most viable and safe therapeutic leads.
Biologically informed
Reducing biological complexity through informed target ID and validation.
“Manas AI enables next-generation multi-modal therapeutics by transforming the pace and precision of drug discovery. For siRNA medicines, this translates into rapid innovation in delivery ligands and nucleic acid chemistry unlocking new levels of specificity, efficacy, and safety.”
“Manas AI’s atomic level frontier models represent a powerful, differentiated approach to tackling AI for drug discovery.”
“Manas is well positioned to uncover subtle structural and mechanistic relationships that were previously undetected with traditional methods, and to drive greater R&D productivity by reducing cycle times, lowering overall costs, and reducing error rates across the drug discovery enterprise.”
Craig Mello, Ph.D.
Nobel Laureate; Co-Founder, Althea Therapeutics
Peter Kim, Ph.D.
Stanford Professor; Former President, Merck Research Laboratories
Ken Frazier
Chairman, Health Assurance Initiatives, General Catalyst; Former Chairman and CEO, Merck
Latest updates
View all